Deciphera Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 35.97 million compared to USD 23.22 million a year ago. Net loss was USD 43.04 million compared to USD 79.84 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 1.37 a year ago.
For the nine months, revenue was USD 97.69 million compared to USD 71.95 million a year ago. Net loss was USD 133 million compared to USD 211.57 million a year ago. Basic loss per share from continuing operations was USD 1.82 compared to USD 3.65 a year ago.